Tag: remibrutinib

Could BTK Inhibitors Change the Future of Drug Desensitization?

drugallergydetective.com
Illustration showing BTK inhibitors as a temporary “anaphylaxis brake” that may reduce immediate allergic reactions during high-risk drug administration and drug desensitization.

BTK inhibitors and drug desensitization are emerging areas of allergy research. Investigators are exploring whether BTK inhibitors can reduce immediate hypersensitivity reactions during high-risk drug administration. Educational Content Disclaimer: This article is for educational purposes only. It is not medical advice and should not replace consultation with a qualified allergist or specialist. The concepts discussed are investigational, hypothesis-generating, and not approved for routine clinical use. This post is intended as a specialist perspective piece, not a practice recommendation. Some patients face a difficult dilemma: they need a medication that could…

Read More

Game Changer: FDA Approves Rhapsido (Remibrutinib), the First Oral BTK Inhibitor for Chronic Hives (CSU)

drugallergydetective.com
FDA approval of Rhapsido (remibrutinib), the first oral BTK inhibitor pill for chronic spontaneous urticaria (CSU).

For years, patients with chronic spontaneous urticaria (CSU) who didn’t respond to antihistamines had only injections as the next step. On September 30, 2025, the U.S. Food and Drug Administration (FDA) approved remibrutinib (brand name Rhapsido), the first oral BTK inhibitor for adults with CSU. This approval offers patients — and doctors — the first convenient oral option beyond antihistamines. What Is Chronic Spontaneous Urticaria (CSU)? Why an Oral Option Matters Until now, patients had only these alternatives: Patients have long asked for a safe oral treatment that avoids injections…

Read More